HCPLive
American Heart Association 2012

American Heart Association 2012 | AHA 2012

According to the AHA, “Scientific Sessions is the leading cardiovascular meeting in the country with over 17,000 professionals attending annually, and over 22,000 total attendees, as reported by the Healthcare Convention and Exhibitor’s Association. Scientific Sessions is the American Heart Association's largest gathering of scientists and healthcare professionals devoted to the science of cardiovascular disease and stroke and the care of patients suffering from these diseases. Programming is designed to improve patient care by communicating the most timely and significant advances in prevention, diagnosis and treatment of cardiovascular disease from many different perspectives.

Conference Coverages

Reducing Cardiovascular Events in Patients with Acute Coronary Syndrome
A substudy of the PLATO trial reveals that treatment with ticagrelor reduces cardiovascular death, myocardial infarction, and stroke in some patients with non-ST-elevation acute coronary syndrome.
Serelaxin Shows Promise in Treating Acute Heart Failure
Results from the RELAX-AHF show serelaxin reduces cardiovascular deaths and improves symptoms in patients with heart failure.
Ticagrelor May Reduce Cardiovascular Events in Patients with Extensive Coronary Artery Disease
Results from a substudy of the PLATO trial show that patients with extensive CAD and high rates of recurrent cardiovascular events, death, and bleeding may benefit from treatment with ticagrelor.
Visible Signs of Aging Can Predict Increased Risk of Heart Disease
Study results presented at the American Heart Association 2012 Scientific Sessions show that visible signs of aging such as baldness and yellow fatty deposits around the eye are predictors for heart attack and heart disease risk.

Most Popular

$vacMongoViewPlus$ $vAR$